Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Phase II study of trastuzumab-pkrb and docetaxel anhydrous combination therapy in recurrent or metastatic salivary ductal carcinomas (KCSG HN18-08/KM11)
Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kang Eun Joo | - |
| dc.date.accessioned | 2022-11-06T18:41:52Z | - |
| dc.date.available | 2022-11-06T18:41:52Z | - |
| dc.date.created | 2022-11-05 | - |
| dc.date.issued | 2022-06-06 | - |
| dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/145016 | - |
| dc.publisher | American Society of Clinical Oncology | - |
| dc.title | Phase II study of trastuzumab-pkrb and docetaxel anhydrous combination therapy in recurrent or metastatic salivary ductal carcinomas (KCSG HN18-08/KM11) | - |
| dc.title.alternative | Phase II study of trastuzumab-pkrb and docetaxel anhydrous combination therapy in recurrent or metastatic salivary ductal carcinomas (KCSG HN18-08/KM11) | - |
| dc.type | Conference | - |
| dc.contributor.affiliatedAuthor | Kang Eun Joo | - |
| dc.identifier.bibliographicCitation | 2022 ASCO annual meeting | - |
| dc.relation.isPartOf | 2022 ASCO annual meeting | - |
| dc.relation.isPartOf | 2022 ASCO annual meeting program book | - |
| dc.citation.title | 2022 ASCO annual meeting | - |
| dc.citation.conferencePlace | US | - |
| dc.citation.conferencePlace | Chicago, USA | - |
| dc.citation.conferenceDate | 2022-06-03 | - |
| dc.type.rims | CONF | - |
| dc.description.journalClass | 1 | - |
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 2. Conference Papers
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.